CompletedPhase 1

A Vasoconstriction Study With LEO 90100

France35 participantsStarted 2013-09

Plain-language summary

The purpose of this study is to compare the pharmacodynamic activity of LEO 90100 with Dermovate® cream, Dovobet® ointment, betamethasone dipropionate in LEO90100 vehicle, Synalar® ointment and LEO 90100 vehicle using a human skin blanching test.

Who can participate

Age range18 Years – 50 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Following verbal and written information about the trial, the subject must provide signed and dated informed consent before any study related activities are carried out. * Healthy male or female volunteers, 18 to 50 years old, both inclusive Exclusion Criteria: * Female subjects who are pregnant or who are breast feeding. * Abnormal pigmentation of the skin or skin type that could, in any way, confound interpretation of the study results (skin type V and VI on the Fitzpatrick scale)

What they're measuring

Visual assessment of skin blanching (visual score (VS))

Timeframe: 06:10, 08:00, 10:00, 12:00, 24:00, 28:00 and 32:00 hours after application

Trial details

NCT IDNCT01946386

SponsorLEO Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2013-10

View on ClinicalTrials.gov More Psoriasis Vulgaris trials